---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Dianthus Therapeutics, Nonproprietary name: proposed and recommended international nonproprietary name, Development code, Structure: fully human IgG4-kappa antibody with an engineered Fc domain, and 1 further topic. 5 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Dianthus Therapeutics

> “Our most advanced product candidate, claseprubart, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “About Claseprubart (DNTH103) Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-2.1.2.1-2"></a>

### Nonproprietary name: proposed and recommended international nonproprietary name

> “claseprubart”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

> “RECOMMENDED International Nonproprietary Names: List 94”
> “immunoglobulin G4-kappa, anti-[Homo sapiens C1S (complement C1s)], Homo sapiens monoclonal antibody”

Source: [WHO Drug Information Recommended INN List 94 (2025)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl94.pdf)

<a id="topic-2.1.2.1-3"></a>

### Development code

> “Drug: Claseprubart IV Infusion Other Names: DNTH103”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.1-4"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-5"></a>

### Structure: fully human IgG4-kappa antibody with an engineered Fc domain

> “Claseprubart is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

> “hinge 1-12 S10>P (225)”
> “M15.1>Y (249), S16>T (251), T18>E (253)”
> “produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa”

Source: [WHO Proposed INN List 132 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf)

<a id="topic-2.1.2.1-6"></a>

### Therapeutic class: classical complement pathway inhibitor targeting active C1s

> “Highly potent, ~8-week half-life, Classical Pathway (CP) inhibitor targeting active C1s”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
